The phase 3 EMBRACA study of talazoparib in BRCA-related metastatic breast cancer - European Medical Journal

The phase 3 EMBRACA study of talazoparib in BRCA-related metastatic breast cancer

Oncology

At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universitä​t Erlangen-Nürnberg, Erlangen, Germany) discuss the clinical development of the poly (ADP-ribose) polymerase (PARP) inhibitor, talazoparib, for the treatment of BRCA-related breast cancer. The ongoing EMBRACA study is a 2:1 phase 3 study comparing the efficacy and safety of the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer.

This programme is supported by BioMarin Pharmaceutical.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>